A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

NCT07223047 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Malignancies
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG: BMS-986523
DRUG: Gemcitabine
DRUG: Nab-Paclitaxel
DRUG: Cetuximab
DRUG: Pembrolizumab

Sponsor

Bristol-Myers Squibb